VC Deals Analysis: Big Boost From Bumper Round
Executive Summary
It had been a slow start to the year but one unusually large financing round from cancer diagnostics company Grail means the first quarter of 2017 has now outpaced the performance from any in the previous four years.
You may also be interested in...
Active Implants Plans 2019 Commercial Release For NUsurface Meniscus Implant
Active Implants announced the completion of patient enrollment in the VENUS randomized trial of the NUsurface meniscus implant for the treatment of persistent knee pain caused by injured or deteriorated meniscus tissue. Results of the VENUS and SUN trial, which has also completed enrollment, will support a de novo clearance from US FDA, which would make it the first artificial meniscus approved in the US. NUsurface already has a CE mark and the company is planning to start a limited commercial release outside the US in 2019.
VC Deals Analysis: Quarter-Billion Round Hikes September Takings To Five-Year High
September benefitted from two nine-figure venture financing rounds, including a $250m round by consumer genetic test service provider 23andme. These bumper deals significantly boost the total takings in 2017 so far to the extent that the year looks likely to beat 2016.
VC Deals Analysis: Strong In Volume, Soft In Value
June marked a month with the highest deal volume this year to date, although the value of most deals wallowed in the low range. Nonetheless the previous bumper months of March and May meant that the first half of 2017 can boast of having raised the most money, compared to the last four years.